FDA Approves AstraZeneca’s Imfinzi for Biliary Tract Cancer Imfinzi, a checkpoint inhibitor developed by AstraZeneca, has been approved by the FDA as the first immunotherapy for biliary tract cancer (BTC), a rare and aggressive form of cancer with few treatment options. Imfinzi (durvalumab) has been approved by ...
Find MorePsoriasis is a debilitating inflammation of skin affecting approximately 7.4 million adults in the United States. Recent researches demonstrating a surge in the Psoriasis prevalence indicating moderate-to-severe psoriasis, absence of safe, effective and easy to administer therapies has clearly resulted in several m...
Find MorePsoriasis is a skin inflammation which is a papulosquamous disease with variable morphology, distribution, severity, course, and duration.According to the WHO report 2016, studies on Psoriasis epidemiology have demonstrated varying prevalence rates across the globe (0.09–11.4%), with an apparent upward trend in sev...
Find MoreGeneralized pustular psoriasis (GPP) is a severe form of rare skin condition caused by abnormal inflammation. It is a type of psoriasis, which is characterized by long-lasting abnormal dry-skin patches all over the body. Bodies of the patients suffering from GPP develop red and tender skin covered with pus-fi...
Find MoreHear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.